HI
TEVA icon

Human Investing’s Teva Pharmaceuticals TEVA Stock Holding History

Human Investing’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50
Closed -$1.1K – 261
2024
Q4 		$1.1K Buy
+50
New +$910 ﹤0.01% 287
2021
Q2 		– Sell
-50
Closed -$1K – 269
2021
Q1 		$1K Hold
50
– – ﹤0.01% 295
2020
Q4 		$0 Sell
50
-100
-67% -$958 ﹤0.01% 328
2020
Q3 		$1K Buy
150
+100
+200% +$1.06K ﹤0.01% 296
2020
Q2 		$1K Hold
50
– – ﹤0.01% 305
2020
Q1 		$0 Hold
50
– – ﹤0.01% 377
2019
Q4 		$0 Hold
50
– – ﹤0.01% 386
2019
Q3 		$0 Hold
50
– – ﹤0.01% 376
2019
Q2 		$0 Hold
50
– – ﹤0.01% 363
2019
Q1 		$1K Hold
50
– – ﹤0.01% 320
2018
Q4 		$1K Buy
+50
New +$1.02K ﹤0.01% 377

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Human Investing's TEVA Position: Q1 2025 in Review

Human Investing sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 50 shares — an estimated $1.1K sold.

Human Investing first reported a position in TEVA in Q4 2018 and held it in 11 quarters. The position peaked at $1.1K in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Human Investing reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Human Investing sold 50 Teva Pharmaceuticals shares in Q1 2025, an estimated $1.1K.
  • Human Investing first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 11 quarters.
  • Human Investing's Teva Pharmaceuticals position peaked at $1.1K in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Human Investing's 13F filing for Q1 2025, filed 15 May 2025.